Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 12

1.

Genetics of Bladder Malignant Tumors in Childhood.

Zangari A, Zaini J, Gulìa C.

Curr Genomics. 2016 Feb;17(1):14-32. doi: 10.2174/1389202916666151014221954.

2.

The Expression of c-Myb Correlates with the Levels of Rhabdomyosarcoma-specific Marker Myogenin.

Kaspar P, Zikova M, Bartunek P, Sterba J, Strnad H, Kren L, Sedlacek R.

Sci Rep. 2015 Oct 14;5:15090. doi: 10.1038/srep15090.

3.

Probing for a deeper understanding of rhabdomyosarcoma: insights from complementary model systems.

Kashi VP, Hatley ME, Galindo RL.

Nat Rev Cancer. 2015 Jul;15(7):426-39. doi: 10.1038/nrc3961. Review.

4.

Myogenin, AP2β, NOS-1, and HMGA2 are surrogate markers of fusion status in rhabdomyosarcoma: a report from the soft tissue sarcoma committee of the children's oncology group.

Rudzinski ER, Anderson JR, Lyden ER, Bridge JA, Barr FG, Gastier-Foster JM, Bachmeyer K, Skapek SX, Hawkins DS, Teot LA, Parham DM.

Am J Surg Pathol. 2014 May;38(5):654-9. doi: 10.1097/PAS.0000000000000195.

5.

Anaplastic rhabdomyosarcoma in TP53 germline mutation carriers.

Hettmer S, Archer NM, Somers GR, Novokmet A, Wagers AJ, Diller L, Rodriguez-Galindo C, Teot LA, Malkin D.

Cancer. 2014 Apr 1;120(7):1068-75. doi: 10.1002/cncr.28507. Epub 2013 Dec 30. Erratum in: Cancer. 2014 Jun 15;120(12):1910.

6.

A novel algorithm for simplification of complex gene classifiers in cancer.

Wilson RA, Teng L, Bachmeyer KM, Bissonnette ML, Husain AN, Parham DM, Triche TJ, Wing MR, Gastier-Foster JM, Barr FG, Hawkins DS, Anderson JR, Skapek SX, Volchenboum SL.

Cancer Res. 2013 Sep 15;73(18):5625-32. doi: 10.1158/0008-5472.CAN-13-0324. Epub 2013 Aug 2.

7.

Zebrafish rhabdomyosarcoma reflects the developmental stage of oncogene expression during myogenesis.

Storer NY, White RM, Uong A, Price E, Nielsen GP, Langenau DM, Zon LI.

Development. 2013 Jul;140(14):3040-50. doi: 10.1242/dev.087858.

8.

Cell-based small-molecule compound screen identifies fenretinide as potential therapeutic for translocation-positive rhabdomyosarcoma.

Herrero Martín D, Boro A, Schäfer BW.

PLoS One. 2013;8(1):e55072. doi: 10.1371/journal.pone.0055072. Epub 2013 Jan 25.

9.

Alveolar rhabdomyosarcoma - The molecular drivers of PAX3/7-FOXO1-induced tumorigenesis.

Marshall AD, Grosveld GC.

Skelet Muscle. 2012 Dec 3;2(1):25. doi: 10.1186/2044-5040-2-25.

10.

In vivo imaging of tumor-propagating cells, regional tumor heterogeneity, and dynamic cell movements in embryonal rhabdomyosarcoma.

Ignatius MS, Chen E, Elpek NM, Fuller AZ, Tenente IM, Clagg R, Liu S, Blackburn JS, Linardic CM, Rosenberg AE, Nielsen PG, Mempel TR, Langenau DM.

Cancer Cell. 2012 May 15;21(5):680-93. doi: 10.1016/j.ccr.2012.03.043.

11.

MicroRNAs in rhabdomyosarcoma: pathogenetic implications and translational potentiality.

Rota R, Ciarapica R, Giordano A, Miele L, Locatelli F.

Mol Cancer. 2011 Sep 24;10:120. doi: 10.1186/1476-4598-10-120. Review.

12.

Pediatric genitourinary tumors.

Castellino SM, Martinez-Borges AR, McLean TW.

Curr Opin Oncol. 2009 May;21(3):278-83. doi: 10.1097/CCO.0b013e328329f201. Review.

Supplemental Content

Support Center